Evestia Clinical, a UK-based pharmaceutical contract research organisation (CRO), backed by Kester Capital, has expanded its global footprint through the acquisition of Atlantic Research Group, a specialist US-based CRO. The merger has resulted in a global footprint for the Evestia brand, with an expanded offering to clients that includes neurology and late-stage clinical trial services. The transaction represents a positive result for Kester Capital, further expanding their life sciences and healthcare portfolio.
"We found Graeme, Lewis, and the whole BDO team to be approachable and knowledgeable throughout the engagement. Their knowledge of the sector was clear to see in their work, and they provided useful insights around the key risk areas of a transaction of this nature. Overall, we felt they added a great deal of value to the process and provided professional guidance and support throughout. They are a pleasure to work with and were an enormous help in getting us to a successful outcome."
David Fernie, VP, Kester Capital
"It has been a pleasure supporting the Kester Capital team with their investment, as well as getting to know the ARG team and business. This transaction was a great opportunity to utilise our existing sector expertise within Life Sciences and Healthcare sector. We look forward to seeing the new, global Evestia Clinical grow and succeed following this transaction."
Graeme Hurst, Partner, BDO LLP
The BDO project team included:
Graeme Hurst, Lewis Winston, Will Hyatt, Daniel Anderson, Hannah Ibrahim (Financial due diligence)
Sam Boundy, Kevin Johnstone (Tax)
Ross McDonald, Alastair Feasey, Tom Wright, Anish Mehta, Seb Walker (Debt advisory)